RIGEL PHARMACEUTICALS INCRIGLEarnings & Financial Report
Nasdaq
RIGL Q3 2025 Key Financial Metrics
Revenue
$69.5M
Gross Profit
$64.7M
Operating Profit
$28.4M
Net Profit
$27.9M
Gross Margin
93.2%
Operating Margin
40.9%
Net Margin
40.2%
YoY Growth
25.6%
EPS
$1.46
Financial Flow
RIGEL PHARMACEUTICALS INC Q3 2025 Financial Summary
RIGEL PHARMACEUTICALS INC reported revenue of $69.5M for Q3 2025, with a net profit of $27.9M (40.2% margin). Cost of goods sold was $4.8M, operating expenses totaled $36.3M.
Key Financial Metrics
| Total Revenue | $69.5M |
|---|---|
| Net Profit | $27.9M |
| Gross Margin | 93.2% |
| Operating Margin | 40.9% |
| Report Period | Q3 2025 |
RIGEL PHARMACEUTICALS INC Annual Revenue by Year
RIGEL PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $179.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $179.3M |
| 2023 | $116.9M |
| 2022 | $120.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.8M | $29.5M | $36.8M | $55.3M | $57.6M | $53.3M | $101.7M | $69.5M |
| YoY Growth | -30.2% | 13.3% | 37.0% | 96.6% | 60.9% | 80.6% | 176.0% | 25.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $117.2M | $126.5M | $128.4M | $139.4M | $164.0M | $176.0M | $206.7M | $242.5M |
| Liabilities | $145.9M | $158.2M | $158.3M | $154.1M | $160.7M | $157.4M | $124.8M | $124.9M |
| Equity | $-28.6M | $-31.7M | $-29.9M | $-14.6M | $3.3M | $18.6M | $81.9M | $117.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.2M | $-5.0M | $302000 | $21.7M | $14.5M | $-893000 | $30.5M | $24.0M |